Phase I study in the continual administration of BK-UM against HB-EGF for patients with advanced or recurrent ovarian cancer - Phase I study in the continual administration of BK-UM against HB-EGF for patients with recurrent ovarian cancer

Fukuoka University Hospital0 个研究点目标入组 24 人开始时间: 2008年2月4日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. exclude the patients who have serious illness or suspect to have serious illness menthioned below (1)exclude the patients who have ischemic heart diseases ro arrythmia to give medical treatment (2)exclude the patients who have less than 50% in ejection fraction using echocardiogram (3)exclude the patients who have cardiac dysfunction as grade III or IV of NYHA or have cardiac infarction within 6 months (4)exclude the patients who have liver schirosis beyond medical control (5)exclude the patients who need the oxigen supplement because of pulmonary intestitial pneumonitis or fiibrosis (6) exclude the patients who need or do medical treatment for mental diseases (7) exclude the patients who have serious diabetes beyond medical control (8) exclude the patients who have ileus or subileus (9)exclude the patients who have serious infection beyond medical control 2. exclude the patients who have progression of disease in clinical trial using BK-UM (Phase I study). 3. exclude the patients who have pregnancy or nursing or have possiblity to be pregnant 4. exclude the patients who are recognized as inadequate patients by doctors wth resposibility in this clinical trial

发起方